News Column

Study Results from University of Queensland Update Understanding of Cancer Gene Therapy

June 16, 2014



By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news reporting out of Brisbane, Australia, by NewsRx editors, research stated, "Curcumin (CUR), a naturally derived anti-cancer cocktail is arguably the most widely studied neutraceutical. Despite a lot of promises, it is yet to reach the market as an active anti-cancer formulation."

Our news journalists obtained a quote from the research from the University of Queensland, "In the present study, we have prepared highly soluble (3 mg/mI) CUR-gamma-hydroxypropyl cyclodextrin (CUR-CD) hollow spheres. CUR-CD hollow spheres were prepared by a novel and scalable spray drying method. CUR-CD was then encapsulated into positively charged biodegradable chitosan (CUR-CD-CS) nanoparticles. The CUR-CD-CS nanoparticles were characterised by TEM, SEM, DLS, drug loading and in vitro release. We tested the efficacy of these CUR-CD-CS nanoparticles in SCC25 cell lines using MTT assay and investigated its cellular uptake mechanism. We also studied Oligo DNA loading in CUR-CD-CS nanoparticles and its delivery via confocal imaging and FACS analysis. Our results demonstrated that CUR-CD-CS nanoparticles showed superior in vitro release performance and higher cytotoxicity in SCC25 cell line amongst all tested formulations. The cytotoxicity results were corroborated by cell cycle analysis and apoptosis test, showing nearly 100% apoptotic cell death in the case of CUR-CD-CS nanoparticles. Compared to CS nanoparticles, CS-CD nanoformulation showed higher cellular delivery of Cy3-Oligo DNA which was tested quantitatively using flowcytometry analysis, indicating that CD not only enhanced CUR solubility but also boosted the cellular uptake."

According to the news editors, the research concluded: "Our study shows that rationally designed bio-degradable natural biomaterials have great potential as next generation nano-carriers for hydrophobic drug delivery such as CUR with potential of dual drug-gene delivery."

For more information on this research see: Curcumin-cyclodextrin encapsulated chitosan nanoconjugates with enhanced solubility and cell cytotoxicity. Colloids and Surfaces B-Biointerfaces, 2014;117():520-527. Colloids and Surfaces B-Biointerfaces can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands (see also Biotechnology).

Our news journalists report that additional information may be obtained by contacting A. Popat, University of Queensland, Translat Res Inst, Mater Res Inst, Mucosal Dis Grp, Brisbane, Qld 4102, Australia. Additional authors for this research include S. Karmakar, S. Jambhrunkar, C. Xu and C.Z. Yu.

Keywords for this news article include: Biotechnology, Alkanes, Brisbane, Curcumin, Catechols, Hydrocarbons, Nanoparticle, Bioengineering, Nanotechnology, Diarylheptanoids, Organic Chemicals, Cancer Gene Therapy, Emerging Technologies, Australia and New Zealand

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters